Przemysław Zygmunciak, Justyna Iskrzak, Joanna Góra-Tybor, Ewa Lech-Marańda, B. Puła
{"title":"将Ruxolitinib作为原发性骨髓纤维化患者多发性骨髓瘤的主要治疗方法？病例报告和文献综述","authors":"Przemysław Zygmunciak, Justyna Iskrzak, Joanna Góra-Tybor, Ewa Lech-Marańda, B. Puła","doi":"10.5603/hicp.95649","DOIUrl":null,"url":null,"abstract":"An 80-year-old female with a history of primary myelofibrosis was admitted to the hospital due to worsening symptoms of the primary disease. A secondary tumor — multiple myeloma (MM) — was revealed during the diagnostic process. Monotherapy with a JAK inhibitor (ruxolitinib) was administered, and the severity of both malignancies was alleviated. This article includes a short review of secondary malignancies correlated with PMF and the state of knowledge on using JAK inhibitors, mainly ruxol-itinib, in treating MM","PeriodicalId":284891,"journal":{"name":"Hematology in Clinical Practice","volume":"115 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ruxolitinib as a primary treatment for multiple myeloma in a patient with primary myelofibrosis? A case report and the review of the literature\",\"authors\":\"Przemysław Zygmunciak, Justyna Iskrzak, Joanna Góra-Tybor, Ewa Lech-Marańda, B. Puła\",\"doi\":\"10.5603/hicp.95649\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"An 80-year-old female with a history of primary myelofibrosis was admitted to the hospital due to worsening symptoms of the primary disease. A secondary tumor — multiple myeloma (MM) — was revealed during the diagnostic process. Monotherapy with a JAK inhibitor (ruxolitinib) was administered, and the severity of both malignancies was alleviated. This article includes a short review of secondary malignancies correlated with PMF and the state of knowledge on using JAK inhibitors, mainly ruxol-itinib, in treating MM\",\"PeriodicalId\":284891,\"journal\":{\"name\":\"Hematology in Clinical Practice\",\"volume\":\"115 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematology in Clinical Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5603/hicp.95649\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology in Clinical Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/hicp.95649","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Ruxolitinib as a primary treatment for multiple myeloma in a patient with primary myelofibrosis? A case report and the review of the literature
An 80-year-old female with a history of primary myelofibrosis was admitted to the hospital due to worsening symptoms of the primary disease. A secondary tumor — multiple myeloma (MM) — was revealed during the diagnostic process. Monotherapy with a JAK inhibitor (ruxolitinib) was administered, and the severity of both malignancies was alleviated. This article includes a short review of secondary malignancies correlated with PMF and the state of knowledge on using JAK inhibitors, mainly ruxol-itinib, in treating MM
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
